GENFIT focuses EASL 2026 on ACLF definition work through consensus meeting with five hepatology societies to unify global disease...

Scilex distributes 10.7 million Semnur shares as dividend to shareholders while retaining majority control of the SEMDEXA developer.

Astellas targets 10+ Phase 3 trials by 2030 under its five-year strategic plan, with five pivotal studies to initiate...

Liminatus Pharma acquires InnocsAI's CAR-T portfolio for $320 million in all-stock deal, gaining dual-target hematologic and solid-tumor programs.

GENFIT's royalty revenue surges 243% on Iqirvo sales growth, reaching €9.6M in Q1 2026 as Ipsen's commercial engine drives...

Nature Reviews flags incretin multi-agonist reversal of obesity and diabetes — Lilly's retatrutide Phase 3 data signals the GLP-1...

Scilex distributes 10.7M Semnur shares via stock dividend with June 1, 2026 record date, retaining dominant ownership of the...

Liminatus Pharma acquires InnocsAI in $320M all-stock deal to gain CAR-T pipeline including IBC101 dual-antigen therapy for blood cancers.

GENFIT collects €17M Ipsen milestone as Iqirvo royalties surge 243% YoY, bolstering cash reserves to €136.1M through Q1 2026.

PharmAla licenses ALA-002 MDMA rights to Jupiter Neurosciences in a deal valued over $100M with $1.5M upfront cash and...